Review article: Delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 9, 2011, Pages 996-1009

  Harris, M S ^a,c   Lichtenstein, G R ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; BUDESONIDE; CORTICOSTEROID; MESALAZINE; PLACEBO;

ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EVENING DOSAGE; HUMAN; MORNING DOSAGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCTITIS; QUALITY OF LIFE; SIGMOID; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG PRESCRIPTIONS; HUMANS; MESALAMINE; TREATMENT OUTCOME;

EID: 79953696521     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04619.x     Document Type: Article

References (80)

1. Lichtenstein GR, Kamm MA,. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis-methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther 2008; 28: 663-73.
2. Nielsen OH,. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1982; 17: 389-93. (Pubitemid 12104966)
3. Ishaq S, Green JR,. Tolerability of aminosalicylates in inflammatory bowel disease. BioDrugs 2001; 15: 339-49. (Pubitemid 32634793)
4. DeVos M, Verdievel H, Schoonjans R, et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992; 33: 1338-42.
5. Frieri G, Pimpo MT, Palumbo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 1999; 13: 1413-7. (Pubitemid 29516252)
6. Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN,. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993; 38: 1989-93. (Pubitemid 23336560)
7. Haddish-Berhane N, Farhadi A, Nyquist C, Haghighi K, Keshavarzian A,. Biological variability and targeted delivery of therapeutics for inflammatory bowel diseases: an in silico approach. Inflamm Allergy Drug Targets 2007; 6: 47-55. (Pubitemid 46488298)
8. Sandborn WJ, Hanauer SB,. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17: 29-42. (Pubitemid 36140432)
9. Stretch GL, Campbell BJ, Dwarkanath AD, et al. 5-aminosalicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine, or mesalazine. Aliment Pharmacol Ther 1996; 10: 941-7. (Pubitemid 26412923)
10. Christenson LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-amino salicylate: comparisons of three controlled release preparations. Aliment Pharmacol Ther 1990; 4: 523-33. (Pubitemid 20337598)
11. Rao SSC, Read NW, Brown C, Bruce C, Holdsworth CD,. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 1987; 93: 934-40. (Pubitemid 18000634)
12. Rao SSC, Read NW,. Gastrointestinal motility in patients with ulcerative colitis. Scand J Gastroenterol 1990; 25 (Suppl. 172): 22-8. (Pubitemid 20206662)
13. Marshall JK, Irvine EJ,. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 292-300.
14. Cohen RD, Woseth DM, Thisted RA, Hanauer SB,. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-76. (Pubitemid 30263523)
15. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998; 41: 93-7. (Pubitemid 28044882)
16. Kam L, Cohen H, Dooley C, Rubin P, Orchard J,. A comparison of mesalamine suspension enema and oral sulfasalzine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996; 91: 1338-42. (Pubitemid 26236365)
17. Safdi M, DeMicco M, Sninsky C, et al. A double blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71. (Pubitemid 27440908)
18. Regueiro M, Loftus EV, Steinhart AH, Cohen RD,. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement. Inflamm Bowel Dis 2006; 12: 972-8. (Pubitemid 44498286)
19. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
20. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5. (Pubitemid 40873909)
21. Farrokh-Yar F, Swarbrick ET, Grace RH, et al. Excellent outcome of first attack of ulcerative colitis in three regional cohorts. Gastroenterology 1999; 116: A711.
22. Ghosh S, Shand A, Ferguson A,. Ulcerative colitis. Br Med J 2000; 320: 1119-23.
23. IMS Research. Prescription trends in 5-ASA use. Wellingborough, England, UK, 1992-2009.
24. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
25. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60.
26. Allez M, Lemann M,. Role of endoscopy in predicting disease course in inflammatory bowel disease. World J Gastroenterol 2010; 16: 2626-32.
27. Lichtenstein GR, Rutgeerts P,. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16: 338-46.
28. Campieri M, Paoluzi P, D'albasio G, Brunetti G, Pera A, Barbara L,. Better quality of life with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema. Dig Dis Sci 1993; 38: 1843-50. (Pubitemid 23311936)
29. Campieri M, Gionchetti P, Belluzzi A, et al. 5-aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol 1988; 10: 406-9.
30. Hanauer SB,. Dose-ranging study of mesalamine (Pentasa) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multi-centered placebo-controlled trial. Inflamm Bowel Dis 1998; 4: 79-83. (Pubitemid 128699839)
31. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; 1: CD004115.
32. Marshall JK, Irvine EJ,. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95: 1628-36. (Pubitemid 30484995)
33. Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enemas in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-8. (Pubitemid 17072238)
34. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85.
35. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 3078-86. (Pubitemid 35424579)
36. D'Haens GD, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild to moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006; 24: 1087-97. (Pubitemid 44386534)
37. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102. (Pubitemid 46096842)
38. Lamet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis 2005; 11: 625-30. (Pubitemid 40961075)
39. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997; 11: 1053-7. (Pubitemid 27525110)
40. Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999; 13: 381-8. (Pubitemid 29142048)
41. Ardizzone S, Doldo P, Ranzi T, et al. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group. Ital J Gastroenterol Hepatol 1999; 31: 677-84.
42. Williams CN, Haber G, Aquino JA,. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci 1987; 32 (Suppl.): 71S-5S.
43. Brown J, Haines S, Wilding IR,. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol Ther 1997; 11: 685-91. (Pubitemid 27376355)
44. Marshall JK, Irvine EJ,. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997; 40: 775-81. (Pubitemid 27305471)
45. Lamers C, Meijer J, Engels L, et al. Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis. Gastroenterology 1991; 100: A22.
46. Lemann M, Galian A, Rutgeerts P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 557-62.
47. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005; 11: 421-7. (Pubitemid 40704075)
48. Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31: 260-6.
49. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Am J Gastroenterol 2000; 95: 469-73. (Pubitemid 30106178)
50. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988; 94: 1075-9.
51. D'Arienzo A, Panarese A, D'Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a doubleblind placebo-controlled trial. Am J Gastroenterol 1990; 85: 1079-82. (Pubitemid 20348389)
52. Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomised double-blind placebo controlled multicentre study. Gut 1998; 42: 195-9. (Pubitemid 28212173)
53. D'Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. Am J Gastroentero 1998; 93: 799-803. (Pubitemid 29063925)
54. Andreoli A, Spinella S, Levenstein S, et al. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis. Ital J Gastroenterol 1994; 26: 121-5. (Pubitemid 24196092)
55. D'Albasio G, Trallori G, Ghetti A, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990; 44: 494-7.
56. Mantzaris GH, Hatzis A, Petraki K, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994; 37: 58-62. (Pubitemid 24064272)
57. D'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143-7. (Pubitemid 27304810)
58. Miner P, Daly R, Nester T, et al. The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology 1994; 106: A736.
59. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005; 201: 1205-15. (Pubitemid 40629065)
60. Wallace JL,. Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin North Am 2001; 30: 971-80. (Pubitemid 33127198)
61. Horn H, Preclick G, Stange F, Ditschuneit H,. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes. Scand I Gastroenterol 1991; 26: 867-79.
62. Stenson WF, Lobos E,. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69: 494-7. (Pubitemid 12177629)
63. Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ,. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50-4.
64. Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL,. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992; 33: 929-32.
65. Fox CC, Moore WC, Lichtenstein LM,. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991; 36: 179-84.
66. Kaiser GC, Yan F, Polk DB,. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999; 116: 602-9. (Pubitemid 29106768)
67. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1- stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999; 274: 26448-53.
68. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98: 1162-9. (Pubitemid 20143098)
69. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47: 410-4.
70. Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 2001; 7: 221-5. (Pubitemid 32776515)
71. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 391-6.
72. Mulder CJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988; 95: 1449-53. (Pubitemid 19016199)
73. Sutherland L, May GR, Shaffer EA,. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Int Med 1993; 188: 540-9. (Pubitemid 23085797)
74. Travis SP, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282-6. (Pubitemid 24277345)
75. Hussain FN, Ajjan RA, Riley SA,. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Br J Clin Pharmacol 2000; 49: 323-30. (Pubitemid 30195274)
76. Greenfield SM, Hamblin AS, Shakoor ZS, et al. Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor α: a novel mechanism of action of sulphasalazine. Gut 1993; 34: 252-6. (Pubitemid 23049122)
77. Kornbluth A, Cuffari C, George J, et al. A prospective, blinded assessment of distal colonic mucosal concentrations of 5-ASA and NAC-5ASA in UC patients treated with either balsalazide (Colazal) or a pH-dependent mesalamine (Asacol). Gastroenterology 2006; 130 (Suppl. 2): 1356.
78. Staerk Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271-6.
79. Vitti RA, Meyers F, Knight LC, et al. Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis. Dig Dis Sci 1989; 34: 1792-7. (Pubitemid 19275343)
80. Connolly MP, Poole CD, Currie CJ, et al. Quality of life improvements attributed to combination therapy with oral and topical mesalamine in mild-to-moderately active ulcerative colitis. Digestion 2009; 80: 241-6.